These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 4611539)
1. Immobilization of enzymes, adsorbents, or both within semipermeable microcapsules (artificial cells) for clinical and experimental treatment of metabolite-related disorders. Chang TM Birth Defects Orig Artic Ser; 1973 Mar; 9(2):66-76. PubMed ID: 4611539 [No Abstract] [Full Text] [Related]
2. 51 Cr-L-asparagine accumulation by tumors: the influence of L-asparaginase treatment. Anghileri LJ J Nucl Biol Med; 1970; 14(4):150-2. PubMed ID: 5538035 [No Abstract] [Full Text] [Related]
3. Development of urease-chitosan membrane. Krajewska B; Leszko M; Zaborska W Polim Med; 1990; 20(1-4):31-41. PubMed ID: 2129516 [TBL] [Abstract][Full Text] [Related]
4. The in vivo effects of semipermeable microcapsules containing L-asparaginase on 6C3HED lymphosarcoma. Chang TM Nature; 1971 Jan; 229(5280):117-8. PubMed ID: 4923094 [No Abstract] [Full Text] [Related]
5. The development and first clinical use of semipermeable microcapsules (artificial cells) as a compact artificial kidney. Chang TM; Malave N Trans Am Soc Artif Intern Organs; 1970; 16():141-8. PubMed ID: 5454159 [No Abstract] [Full Text] [Related]
6. Uptake of asparagine C-14 into the pyrimidine synthesis pathway of guinea pig serum sensitive 6C3HED lymphosarcoma cells. Woods JS; Dixon RL Proc West Pharmacol Soc; 1968; 11():67-8. PubMed ID: 5757098 [No Abstract] [Full Text] [Related]
7. [Use of immobilized enzymes in detoxification. II. Immobilization and characterization of enzymes on hollow fiber devices]. Mazzola G; Cremonesi P; Colombi S; Vecchio G; Agnellini D; Pietta PG Minerva Nefrol; 1979; 26(2):185-7. PubMed ID: 471347 [No Abstract] [Full Text] [Related]
8. Methods for the therapeutic applications of immobilized enzymes. Chang TM Methods Enzymol; 1976; 44():676-98. PubMed ID: 1021699 [No Abstract] [Full Text] [Related]
9. Inhibition of thymidine and basic amino acid metabolism in P1798 lymphosarcoma by L-asparaginase. Mashburn LT; Landin LM Cancer Res; 1974 Feb; 34(2):313-8. PubMed ID: 4589953 [No Abstract] [Full Text] [Related]
10. The effects of L-asparaginase on the amino acid incorporation of mouse lymphoid tumors. Mashburn LT; Gordon CS Cancer Res; 1968 May; 28(5):961-7. PubMed ID: 5652310 [No Abstract] [Full Text] [Related]
16. Inhibition of lymphoma 6C3HED by L-asparaginase from Serratia marcescens. Boyd JW; Phillips AW J Natl Cancer Inst; 1971 Jun; 46(6):1271-6. PubMed ID: 4932428 [No Abstract] [Full Text] [Related]
17. [Metabolism of amino acids and urea cycle: animal models of enzymopathies]. Kamoun PP Ann Biol Clin (Paris); 1992; 50(2):63-70. PubMed ID: 1443794 [TBL] [Abstract][Full Text] [Related]
18. L-Asparaginase: discovery and development as a tumor-inhibitory agent. Broome JD Cancer Treat Rep; 1981; 65 Suppl 4():111-4. PubMed ID: 7049374 [No Abstract] [Full Text] [Related]
19. Asparagine incorporation into the DNA of hepatic and 6C3HED murine lymphosarcoma cells. Woods JS; Lee IP; Dixon RL Cancer Res; 1970 Apr; 30(4):1210-1. PubMed ID: 5537321 [No Abstract] [Full Text] [Related]
20. On the clinical use of microencapsulated zirconium phosphate-urease for the treatment of chronic uremia. Kjellstrand C; Borges H; Pru C; Gardner D; Fink D Trans Am Soc Artif Intern Organs; 1981; 27():24-30. PubMed ID: 7036498 [No Abstract] [Full Text] [Related] [Next] [New Search]